Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours-Reference-Cited by-同舟云学术

Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours

Published:2022-03 Issue: Volume:104 Page:102340
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Crucitta Stefania,Cucchiara Federico,Mathijssen Ron,Mateo Joaquin,Jager Agnes,Joosse Arjen,Passaro Antonio,Attili Ilaria,Petrini Iacopo,van Schaik Ron,Danesi Romano,Del Re Marzia

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference224 articles.

1. Recent advances in precision oncology research;Bode;NPJ Precis Oncol.,2018

2. Somatic alterations as the basis for resistance to targeted therapies;Blair;J Pathol.,2014

3. Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies;Asić;Crit Rev Oncol Hematol.,2016

4. Genetic instability and darwinian selection in tumours;Cahill;Trends Cell Biol.,1999

5. Accumulation of driver and passenger mutations during tumor progression;Bozic;Proc Natl Acad Sci U S A.,2010

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic reprogramming of poly(morpho)nuclear giant cells determines glioblastoma recovery from doxorubicin-induced stress;Journal of Translational Medicine;2024-08-12

2. Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings;Cancers;2024-07-19

3. Identification of a basement membrane-related gene signature for predicting prognosis, immune infiltration, and drug sensitivity in colorectal cancer;Frontiers in Oncology;2024-07-01

4. A novel Senescence-Based prognostic model unveils tumor interactions and drug resistance in colorectal cancer;International Immunopharmacology;2024-06

5. Dual targetable drug delivery system based on cell membrane camouflaged liposome for enhanced tumor targeting and improved anti-tumor efficiency;Colloids and Surfaces B: Biointerfaces;2024-06